0000899243-16-019018.txt : 20160502 0000899243-16-019018.hdr.sgml : 20160502 20160502210455 ACCESSION NUMBER: 0000899243-16-019018 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20160420 FILED AS OF DATE: 20160502 DATE AS OF CHANGE: 20160502 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMEDISYS INC CENTRAL INDEX KEY: 0000896262 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 113131700 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5959 S SHERWOOD FOREST BLVD CITY: BATON ROUGE STATE: LA ZIP: 70816 BUSINESS PHONE: 2252922031 MAIL ADDRESS: STREET 1: 5959 S SHERWOOD FOREST BLVD CITY: BATON ROUGE STATE: LA ZIP: 70816 FORMER COMPANY: FORMER CONFORMED NAME: ANALYTICAL NURSING MANAGEMENT CORP DATE OF NAME CHANGE: 19940819 FORMER COMPANY: FORMER CONFORMED NAME: M&N CAPITAL CORP DATE OF NAME CHANGE: 19930125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Carmody Jane CENTRAL INDEX KEY: 0001673393 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24260 FILM NUMBER: 161613374 MAIL ADDRESS: STREET 1: 5959 S. SHERWOOD FOREST BLVD CITY: BATON ROUGE STATE: LA ZIP: 70816 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2016-04-20 0 0000896262 AMEDISYS INC AMED 0001673393 Carmody Jane 5959 S. SHERWOOD FOREST BLVD BATON ROUGE LA 70816 0 1 0 0 See Remarks Common Stock 2469 D Stock Option (Right to Buy) 40.51 2025-10-21 Common Stock 4660 D Restricted Stock Units Common Stock 7406 D Includes 2,469 shares of time-based Restricted Stock Units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock, and will vest in equal, 25% installments on each of October 21, 2016, October 21, 2017, October 21, 2018 and October 21, 2019, provided that the Reporting Person remains continuously employed by the Issuer on each such date, subject to certain pro-rated vesting provisions as provided in the award agreement for the RSUs. The Stock Options are subject to time-based vesting conditions and will vest in equal, 25% installments on each of October 21, 2016, October 21, 2017, October 21, 2018 and October 21, 2019, provided that the Reporting Person remains continuously employed by the issuer on each such date, subject to pro-rated vesting provisions as provided in the award agreement for the Stock Options. The RSUs awarded are subject to performance-based vesting and will vest (i) on the certification by the Compensation Committee of the Issuer's Board of Directors of the achievement of identified performance goals for fiscal year 2015 and (ii) additional time-based vesting conditions (25% installments on each of October 21, 2016, October 21, 2017, October 21, 2018 and October 21, 2019), assuming the Reporting Person remains continuously employed by the Issuer on each such date, subject to certain pro-rated vesting provisions as provided in the award agreement for the RSUs. Chief Clinical Operations Officer /s/ Jennifer R. Guckert, pursuant to a power of attorney 2016-05-02 EX-24 2 attachment1.htm EX-24 DOCUMENT

                                 POWER OF ATTORNEY

       Know all by these presents, that the undersigned hereby constitutes and
appoints each of Jennifer R. Guckert and David L. Kemmerly, signing singly, the
undersigned's true and lawful attorney-in-fact to:

1.     execute for and on behalf of the undersigned, in the undersigned's
       individual capacity, Forms 3, 4 and 5 in accordance with Section 16(a) of
       the Securities Exchange Act of 1934, as amended, and the rules and
       regulations promulgated thereunder (the "Exchange Act");

2.     do and perform any and all acts for and on behalf of the undersigned
       which may be necessary or desirable to complete and execute any Forms 3,
       4 or 5, complete and execute any amendment or amendments thereto, and
       timely file such form with the U.S. Securities and Exchange Commission
       and any stock exchange or similar authority; and

3.     take any and all other actions of any type whatsoever in connection with
       the foregoing which, in the opinion of such attorney-in-fact, may be of
       benefit to, in the best interest of, or legally required by, the
       undersigned, it being understood that the documents executed by such
       attorney-in-fact on behalf of the undersigned pursuant to this Power of
       Attorney shall be in such form and shall contain such terms and
       conditions as such attorney-in-fact may approve in such
       attorney-in-fact's discretion.

       The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall l
awfully do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted.  The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming any of the undersigned's responsibilities to
comply with Section 16 of the Exchange Act.

       This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by Amedisys,
Inc., unless earlier revoked by the undersigned in a signed writing delivered to
the foregoing attorneys-in-fact.

       IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed on April 20, 2016.

/s/ Jane Carmody
-------------------------
Jane Carmody